Maryam Zarei, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,850 of the $13,396 with a category attached, or 81.0%. It is spread thinly across 33 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,082 and has fallen 63.7% since, to $1,120 in 2025.
Across 526 payments — averaging $25.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- GSK$2K
- Genentech USA, Inc.$2K
- AstraZeneca$2K
- Pfizer$943
- Takeda Pharmaceuticals U.S.A., Inc.$529
- plus $5K from 27 others
What the payments were for
- Consulting fees$2,47018%
- Food & beverage$10,85081%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 45 | $1,977 |
| GSK | 64 | $1,768 |
| Genentech USA, Inc. | 16 | $1,721 |
| AstraZeneca | 71 | $1,671 |
| Pfizer | 51 | $943 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $529 |
| CSL Behring | 17 | $489 |
| Grifols USA, LLC | 31 | $482 |
| Kaleo, Inc. | 28 | $417 |
| Optinose US, Inc. | 22 | $365 |
| Regeneron Healthcare Solutions, Inc. | 23 | $352 |
| Alk-abello, Inc | 18 | $283 |
| Novartis | 10 | $274 |
| Shire North American Group Inc | 19 | $254 |
| Incyte Corporation | 17 | $225 |
| Genentech, Inc. | 3 | $216 |
| Amgen(2 entities) | 5 | $211 |
| Blueprint Medicines Corporation | 6 | $172 |
| AbbVie(2 entities) | 10 | $167 |
| Pharming Healthcare, Inc. | 5 | $141 |
| Boehringer Ingelheim | 9 | $137 |
| Seqirus USA Inc | 5 | $103 |
| LEO Pharma Inc. | 4 | $102 |
| Teva Pharmaceuticals USA, Inc. | 5 | $89 |
| Biocryst US Sales Co., LLC | 3 | $64 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $52 |
| Octapharma USA, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Galderma Laboratories, L.p. | 2 | $35 |
| Aimmune Therapeutics, Inc. | 2 | $29 |
| Mylan Specialty L.p. | 1 | $18 |
| Organon | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,396 in reported general payments places this provider in the 80th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $60,420 |
| NucalaMepolizumab | 12 | $44,638 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $32,901 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $15,408 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,700 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,176 |
| Arnuity ElliptaFluticasone Furoate | 25 | $5,962 |
| Ipratropium Bromide | 42 | $3,176 |
| Montelukast Sodium | 139 | $1,881 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $840 |
| Levocetirizine Dihydrochloride | 19 | $564 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $463 |
| Fluticasone Propionate | 12 | $392 |
| Gabapentin | 32 | $293 |
| Mirtazapine | 23 | $288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,768 | $98,909110 claims |
| CSL BehringHizentra | $489 | $60,42014 claims |
| Boehringer IngelheimSpiriva Respimat | $137 | $6,70013 claims |
| AstraZenecaSymbicort | $1,671 | $6,17618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 117 allergy providers in California.
Other allergy in Poway
- Joshua JacobsWalnut Creek$1.5M
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
- Stephen WongHacienda Heights$50K
- Michelle YasharpourBeverly Hills$48K
- Stuart EpsteinBeverly Hills$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.